(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...
Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...
As the cold and flu season approaches, LeadingAge has announced a partnership with the U.S. Department of Health and Human Services (HHS) to launch the "Risk Less. Do More.” campaign. This national ...
released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (RespiratorySyncytialVirus Vaccine) when co ...
Results that may be inaccessible to you are currently showing.